Company intelligence / Profile preview

Trimax

Raichur, Karnataka, India

Ownership: Private
Development stage: Other

Overview

US FDA, EMEA, and WHO GMP-compliant manufacturing of diversified APIs, with recent expansion under Sigachi’s ownership; supplies key small molecule actives for major therapeutic areas, including cardiovascular, CNS, anti-infective, antiviral, antidiabetic, and their intermediates

Therapeutic areas: EndocrinologyCardiovascularNeurologyInfectious DiseasesOncologyMen's Health
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Partnerships

MylanMatrixVorin LabsDivisNatco

Beyond the preview

Go deeper on Trimax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trimax.

Explore the full profile